NICE work by Novartis pays off for Gilenya
This article was originally published in Scrip
Executive Summary
Novartis may have finally convinced NICE, the health technology appraisal institute for England and Wales, about the cost-effectiveness of its treatment for relapsing-remitting multiple sclerosis (RRMS), Gilenya (fingolimod).